Copyright Reports & Markets. All rights reserved.

Global Chronic Obstructive Pulmonary Disorder Market Size, Status and Forecast 2019-2025

Request for Sample of this report
Buy now

Table of Contents

    1 Report Overview

    • 1.1 Study Scope
    • 1.2 Key Market Segments
    • 1.3 Players Covered
    • 1.4 Market Analysis by Type
      • 1.4.1 Global Chronic Obstructive Pulmonary Disorder Market Size Growth Rate by Type (2014-2025)
      • 1.4.2 Short-Acting Bronchodilators
      • 1.4.3 Corticosteroids
      • 1.4.4 Methylxanthines
      • 1.4.5 Long-Acting Bronchodilators
      • 1.4.6 Phosphodiesterase-4 Inhibitors
      • 1.4.7 Others
    • 1.5 Market by Application
      • 1.5.1 Global Chronic Obstructive Pulmonary Disorder Market Share by Application (2014-2025)
      • 1.5.2 Hospitals
      • 1.5.3 Clinics
      • 1.5.4 Others
    • 1.6 Study Objectives
    • 1.7 Years Considered

    2 Global Growth Trends

    • 2.1 Chronic Obstructive Pulmonary Disorder Market Size
    • 2.2 Chronic Obstructive Pulmonary Disorder Growth Trends by Regions
      • 2.2.1 Chronic Obstructive Pulmonary Disorder Market Size by Regions (2014-2025)
      • 2.2.2 Chronic Obstructive Pulmonary Disorder Market Share by Regions (2014-2019)
    • 2.3 Industry Trends
      • 2.3.1 Market Top Trends
      • 2.3.2 Market Drivers
      • 2.3.3 Market Opportunities

    3 Market Share by Key Players

    • 3.1 Chronic Obstructive Pulmonary Disorder Market Size by Manufacturers
      • 3.1.1 Global Chronic Obstructive Pulmonary Disorder Revenue by Manufacturers (2014-2019)
      • 3.1.2 Global Chronic Obstructive Pulmonary Disorder Revenue Market Share by Manufacturers (2014-2019)
      • 3.1.3 Global Chronic Obstructive Pulmonary Disorder Market Concentration Ratio (CR5 and HHI)
    • 3.2 Chronic Obstructive Pulmonary Disorder Key Players Head office and Area Served
    • 3.3 Key Players Chronic Obstructive Pulmonary Disorder Product/Solution/Service
    • 3.4 Date of Enter into Chronic Obstructive Pulmonary Disorder Market
    • 3.5 Mergers & Acquisitions, Expansion Plans

    4 Breakdown Data by Type and Application

    • 4.1 Global Chronic Obstructive Pulmonary Disorder Market Size by Type (2014-2019)
    • 4.2 Global Chronic Obstructive Pulmonary Disorder Market Size by Application (2014-2019)

    5 United States

    • 5.1 United States Chronic Obstructive Pulmonary Disorder Market Size (2014-2019)
    • 5.2 Chronic Obstructive Pulmonary Disorder Key Players in United States
    • 5.3 United States Chronic Obstructive Pulmonary Disorder Market Size by Type
    • 5.4 United States Chronic Obstructive Pulmonary Disorder Market Size by Application

    6 Europe

    • 6.1 Europe Chronic Obstructive Pulmonary Disorder Market Size (2014-2019)
    • 6.2 Chronic Obstructive Pulmonary Disorder Key Players in Europe
    • 6.3 Europe Chronic Obstructive Pulmonary Disorder Market Size by Type
    • 6.4 Europe Chronic Obstructive Pulmonary Disorder Market Size by Application

    7 China

    • 7.1 China Chronic Obstructive Pulmonary Disorder Market Size (2014-2019)
    • 7.2 Chronic Obstructive Pulmonary Disorder Key Players in China
    • 7.3 China Chronic Obstructive Pulmonary Disorder Market Size by Type
    • 7.4 China Chronic Obstructive Pulmonary Disorder Market Size by Application

    8 Japan

    • 8.1 Japan Chronic Obstructive Pulmonary Disorder Market Size (2014-2019)
    • 8.2 Chronic Obstructive Pulmonary Disorder Key Players in Japan
    • 8.3 Japan Chronic Obstructive Pulmonary Disorder Market Size by Type
    • 8.4 Japan Chronic Obstructive Pulmonary Disorder Market Size by Application

    9 Southeast Asia

    • 9.1 Southeast Asia Chronic Obstructive Pulmonary Disorder Market Size (2014-2019)
    • 9.2 Chronic Obstructive Pulmonary Disorder Key Players in Southeast Asia
    • 9.3 Southeast Asia Chronic Obstructive Pulmonary Disorder Market Size by Type
    • 9.4 Southeast Asia Chronic Obstructive Pulmonary Disorder Market Size by Application

    10 India

    • 10.1 India Chronic Obstructive Pulmonary Disorder Market Size (2014-2019)
    • 10.2 Chronic Obstructive Pulmonary Disorder Key Players in India
    • 10.3 India Chronic Obstructive Pulmonary Disorder Market Size by Type
    • 10.4 India Chronic Obstructive Pulmonary Disorder Market Size by Application

    11 Central & South America

    • 11.1 Central & South America Chronic Obstructive Pulmonary Disorder Market Size (2014-2019)
    • 11.2 Chronic Obstructive Pulmonary Disorder Key Players in Central & South America
    • 11.3 Central & South America Chronic Obstructive Pulmonary Disorder Market Size by Type
    • 11.4 Central & South America Chronic Obstructive Pulmonary Disorder Market Size by Application

    12 International Players Profiles

    • 12.1 GSK
      • 12.1.1 GSK Company Details
      • 12.1.2 Company Description and Business Overview
      • 12.1.3 Chronic Obstructive Pulmonary Disorder Introduction
      • 12.1.4 GSK Revenue in Chronic Obstructive Pulmonary Disorder Business (2014-2019)
      • 12.1.5 GSK Recent Development
    • 12.2 Pfizer
      • 12.2.1 Pfizer Company Details
      • 12.2.2 Company Description and Business Overview
      • 12.2.3 Chronic Obstructive Pulmonary Disorder Introduction
      • 12.2.4 Pfizer Revenue in Chronic Obstructive Pulmonary Disorder Business (2014-2019)
      • 12.2.5 Pfizer Recent Development
    • 12.3 Merck
      • 12.3.1 Merck Company Details
      • 12.3.2 Company Description and Business Overview
      • 12.3.3 Chronic Obstructive Pulmonary Disorder Introduction
      • 12.3.4 Merck Revenue in Chronic Obstructive Pulmonary Disorder Business (2014-2019)
      • 12.3.5 Merck Recent Development
    • 12.4 Novartis
      • 12.4.1 Novartis Company Details
      • 12.4.2 Company Description and Business Overview
      • 12.4.3 Chronic Obstructive Pulmonary Disorder Introduction
      • 12.4.4 Novartis Revenue in Chronic Obstructive Pulmonary Disorder Business (2014-2019)
      • 12.4.5 Novartis Recent Development
    • 12.5 AstraZeneca
      • 12.5.1 AstraZeneca Company Details
      • 12.5.2 Company Description and Business Overview
      • 12.5.3 Chronic Obstructive Pulmonary Disorder Introduction
      • 12.5.4 AstraZeneca Revenue in Chronic Obstructive Pulmonary Disorder Business (2014-2019)
      • 12.5.5 AstraZeneca Recent Development
    • 12.6 Boehringer Ingelheim
      • 12.6.1 Boehringer Ingelheim Company Details
      • 12.6.2 Company Description and Business Overview
      • 12.6.3 Chronic Obstructive Pulmonary Disorder Introduction
      • 12.6.4 Boehringer Ingelheim Revenue in Chronic Obstructive Pulmonary Disorder Business (2014-2019)
      • 12.6.5 Boehringer Ingelheim Recent Development
    • 12.7 Teva Pharmaceuticals
      • 12.7.1 Teva Pharmaceuticals Company Details
      • 12.7.2 Company Description and Business Overview
      • 12.7.3 Chronic Obstructive Pulmonary Disorder Introduction
      • 12.7.4 Teva Pharmaceuticals Revenue in Chronic Obstructive Pulmonary Disorder Business (2014-2019)
      • 12.7.5 Teva Pharmaceuticals Recent Development
    • 12.8 Ario Pharma
      • 12.8.1 Ario Pharma Company Details
      • 12.8.2 Company Description and Business Overview
      • 12.8.3 Chronic Obstructive Pulmonary Disorder Introduction
      • 12.8.4 Ario Pharma Revenue in Chronic Obstructive Pulmonary Disorder Business (2014-2019)
      • 12.8.5 Ario Pharma Recent Development
    • 12.9 Roche
      • 12.9.1 Roche Company Details
      • 12.9.2 Company Description and Business Overview
      • 12.9.3 Chronic Obstructive Pulmonary Disorder Introduction
      • 12.9.4 Roche Revenue in Chronic Obstructive Pulmonary Disorder Business (2014-2019)
      • 12.9.5 Roche Recent Development
    • 12.10 Ache
      • 12.10.1 Ache Company Details
      • 12.10.2 Company Description and Business Overview
      • 12.10.3 Chronic Obstructive Pulmonary Disorder Introduction
      • 12.10.4 Ache Revenue in Chronic Obstructive Pulmonary Disorder Business (2014-2019)
      • 12.10.5 Ache Recent Development
    • 12.11 Almirall
    • 12.12 Aquinox Pharmaceuticals
    • 12.13 Asmacure
    • 12.14 Astellas Pharma

    13 Market Forecast 2019-2025

    • 13.1 Market Size Forecast by Regions
    • 13.2 United States
    • 13.3 Europe
    • 13.4 China
    • 13.5 Japan
    • 13.6 Southeast Asia
    • 13.7 India
    • 13.8 Central & South America
    • 13.9 Market Size Forecast by Product (2019-2025)
    • 13.10 Market Size Forecast by Application (2019-2025)

    14 Analyst's Viewpoints/Conclusions

      15 Appendix

      • 15.1 Research Methodology
        • 15.1.1 Methodology/Research Approach
          • 15.1.1.1 Research Programs/Design
          • 15.1.1.2 Market Size Estimation
          • 12.1.1.3 Market Breakdown and Data Triangulation
        • 15.1.2 Data Source
          • 15.1.2.1 Secondary Sources
          • 15.1.2.2 Primary Sources
      • 15.2 Disclaimer

      Chronic obstructive pulmonary disease (COPD) is a type of obstructive lung disease characterized by long-term breathing problems and poor airflow. The main symptoms include shortness of breath and cough with sputum production. COPD is a progressive disease, meaning it typically worsens over time.
      The growth of the global chronic obstructive pulmonary disease (COPD) market is expected to be fueled by a high number of new, more efficacious and convenient products entering the market and commanding a greater value compared to the therapies already existing in the market. Another major factor propelling the growth of the market is the introduction of novel innovations like ultrasonic nebulizers, which are superior to the existing jet nebulizers. The competitive environment is expected to intensify with an increase in product extensions, technological innovations, and an increase in the number of mergers and acquisitions. The market for COPD drugs shows potential opportunity in both developed and developing countries. Due to the effectiveness and advancements in technology, many companies are focusing and collaborating to develop innovative COPD drugs and treatments.
      In 2018, the global Chronic Obstructive Pulmonary Disorder market size was xx million US$ and it is expected to reach xx million US$ by the end of 2025, with a CAGR of xx% during 2019-2025.

      This report focuses on the global Chronic Obstructive Pulmonary Disorder status, future forecast, growth opportunity, key market and key players. The study objectives are to present the Chronic Obstructive Pulmonary Disorder development in United States, Europe and China.

      The key players covered in this study
      GSK
      Pfizer
      Merck
      Novartis
      AstraZeneca
      Boehringer Ingelheim
      Teva Pharmaceuticals
      Ario Pharma
      Roche
      Ache
      Almirall
      Aquinox Pharmaceuticals
      Asmacure
      Astellas Pharma

      Market segment by Type, the product can be split into
      Short-Acting Bronchodilators
      Corticosteroids
      Methylxanthines
      Long-Acting Bronchodilators
      Phosphodiesterase-4 Inhibitors
      Others

      Market segment by Application, split into
      Hospitals
      Clinics
      Others

      Market segment by Regions/Countries, this report covers
      United States
      Europe
      China
      Japan
      Southeast Asia
      India
      Central & South America

      The study objectives of this report are:
      To analyze global Chronic Obstructive Pulmonary Disorder status, future forecast, growth opportunity, key market and key players.
      To present the Chronic Obstructive Pulmonary Disorder development in United States, Europe and China.
      To strategically profile the key players and comprehensively analyze their development plan and strategies.
      To define, describe and forecast the market by product type, market and key regions.

      In this study, the years considered to estimate the market size of Chronic Obstructive Pulmonary Disorder are as follows:
      History Year: 2014-2018
      Base Year: 2018
      Estimated Year: 2019
      Forecast Year 2019 to 2025
      For the data information by region, company, type and application, 2018 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.

      Buy now